Kaleido Biosciences Prices $75M IPO Below Range
Clinical-stage biotech company Kaleido Biosciences said late Wednesday that it has priced a $75 million initial public offering that was steered by Goodwin Procter LLP below the expected price range....To view the full article, register now.
Already a subscriber? Click here to view full article